Population pharmacokinetics of oxycodone in children 6 months to 7 years old

被引:31
作者
El-Tahtawy, A
Kokki, H
Reidenberg, BE
机构
[1] Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA
[2] Cornell Univ, Weill Med Coll, Dept Pediat, New York, NY 10021 USA
[3] Metrum Res Grp, Tariffville, CT USA
[4] Kuopio Univ Hosp, Dept Anesthesiol & Intens Care, SF-70210 Kuopio, Finland
[5] Univ Kuopio, Dept Pharmacol & Toxicol, FIN-70211 Kuopio, Finland
关键词
opioid; pediatric; pharmocokinetics;
D O I
10.1177/0091270006286433
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Young children are often undertreated for pain. One barrier to effective pain treatment is understanding the pharmacokinetic behavior of analgesics in this age group. Oxycodone is a commonly prescribed opioid for severe pain, yet little is known about its pharmacokinetics in young children. This article used population pharmacokinetic modeling to synthesize pharmacokinetic data from several studies into a model. A single Population model that described the observed pharmacokinetics was developed. The combined data were best described with a 2-compartment linear model with different first-order absorption rates depending on route of administration. Weight was found to significantly influence both clearance (CL) and volume of distribution (Vd). The following model adequately describes the population pharmacokinetic profile of oxycodone where absolute bioavailability (F) is estimated for each administration route: CL/F = 55 x (body weight/70)(0.87); V/F= 86 x (body weight/70)(1.16). The interindividual coefficients of variation in CL and 114 were 20.2 and 19.7%.. respectively This finding confirms that the allometric scaling using the above model explained most of the variability in exposure observed among children. This model confirms using a vveight-based dose for oxycodone without adjustment for age between 6 months and 7 years and is valuable for evaluating dosing schedules and dosing routes.
引用
收藏
页码:433 / 442
页数:10
相关论文
共 31 条
[1]   A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children [J].
Anderson, BJ ;
Woollard, GA ;
Holford, NHG .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (02) :125-134
[2]   Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children [J].
Anderson, BJ ;
Holford, NHG ;
Woollard, GA ;
Chan, PLS .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (03) :237-243
[3]   Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients [J].
Anderson, BJ ;
McKee, AD ;
Holford, NHG .
CLINICAL PHARMACOKINETICS, 1997, 33 (05) :313-327
[4]   A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery [J].
Bailey, JM ;
Hoffman, TM ;
Wessel, DL ;
Nelson, DP ;
Atz, AM ;
Chang, AC ;
Kulik, TJ ;
Spray, TL ;
Akbary, A ;
Miller, RP ;
Wernovsky, G .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2004, 31 (01) :43-59
[5]  
Blumer JL, 1999, PEDIATRICS, V104, P598
[7]  
Blumer JL, 1999, PEDIATRICS, V104, P582
[8]   Population pharmacokinetics of clofarabine, a second-generation nucleoside analogy, in pediatric patients with acute leukemia [J].
Bonate, PL ;
Craig, A ;
Gaynon, P ;
Gandhi, V ;
Jeha, S ;
Kadota, R ;
Lam, GN ;
Plunkett, W ;
Razzouk, B ;
Rytting, M ;
Steinherz, P ;
Weitman, S .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (11) :1309-1322
[9]  
Christensen ML, 1999, PEDIATRICS, V104, P593
[10]   Extended-interval dosing of tobramycin in neonates: Implications for therapeutic drug monitoring [J].
de Hoog, M ;
Mouton, JW ;
Schoemaker, RC ;
Verduin, CM ;
van den Anker, JN .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (05) :349-358